AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III

"We believe the new AVP III is another strong addition to the AGA vascular plug family," said Franck Gougeon, President and CEO of AGA. "Our goal is to provide physicians with a toolbox of embolization devices that can treat vessels of different types and length and with different flow characteristics."

The AVP III is a self-expanding nitinol mesh device and is designed to be introduced in a minimally invasive fashion through a catheter. The device comes pre-attached to a delivery cable by a small screw; the delivery cable enables the physician to precisely position the device in the targeted blood vessel. Once positioned, the cable is unscrewed and the device is released. The nitinol mesh retention discs ensure the secure positioning of the device even in high flow vessels.

"Our pre-clinical testing suggests that the AVP III will have the fastest occlusion times within our vascular plug family," said Mr. Gougeon.

The AVP III is under review by the Food and Drug Administration for clearance to market in the U.S.

ABOUT AGA MEDICAL: AGA Medical Corporation, based inPlymouth, Minnesota (just outsideMinneapolis), is a leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, AGA develops and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The company is expanding into new areas such as the minimally invasive repair of vascular abnormalities. More than 770 articles have been published in medical publications that support the benefits of AGA devices, including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient. AGA Medical devices have received regulatory approval and are marketed in 101 countries with more than 278,000 devices shipped to date. For more information visit www.amplatzer.com.

     MEDIA CONTACT:
     Jake Sargent
     Brunswick Group LLC
     202.393.7337
     jsargent@brunswickgroup.com

SOURCE AGA Medical Corporation

Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze, Daily News

Tags: Healthcare, Pharmaceuticals, Health, minnesota

   _   _

         

Is your favorite bookmark site missing? Ask for it.